Detalhe da pesquisa
1.
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
Cell
; 157(2): 369-381, 2014 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24703711
2.
Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.
Cell
; 148(1-2): 59-71, 2012 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22265402
3.
PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Blood
; 139(7): 1080-1097, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34695195
4.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438627
5.
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Cell
; 137(5): 821-34, 2009 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-19490892
6.
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Blood
; 137(22): 3093-3104, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33598693
7.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Blood
; 138(26): 2753-2767, 2021 12 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724563
8.
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Ann Hematol
; 102(2): 349-358, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564535
9.
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel.
Am J Hematol
; 98(12): 1847-1855, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37671649
10.
Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia.
Mol Cancer
; 21(1): 166, 2022 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35986270
11.
Defining disease modification in myelofibrosis in the era of targeted therapy.
Cancer
; 128(13): 2420-2432, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35499819
12.
First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.
Cancer Immunol Immunother
; 71(12): 2913-2928, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476127
13.
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Blood
; 136(26): 3041-3050, 2020 12 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33367545
14.
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia.
Blood
; 135(5): 371-380, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826241
15.
The retinoic acid receptor co-factor NRIP1 is uniquely upregulated and represents a therapeutic target in acute myeloid leukemia with chromosome 3q rearrangements.
Haematologica
; 107(8): 1758-1772, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34854277
16.
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
Blood
; 134(19): 1608-1618, 2019 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31554635
17.
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
Blood
; 133(8): 840-851, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30563875
18.
Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
Ann Hematol
; 100(8): 1983-1993, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33839881
19.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
N Engl J Med
; 377(5): 454-464, 2017 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28644114
20.
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.
Blood
; 132(26): 2707-2721, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30366920